Overview

A Single-dose Study of Octreotide Injection in Healthy Adult Subjects

Status:
Not yet recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
This is a single-centre, single-dose, dose-escalation, placebo and positive drug-controlled Phase I clinical study in healthy Chinese subjects to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of octreotide injection in healthy Chinese subjects.
Phase:
Phase 1
Details
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Treatments:
Octreotide